Medical education article updated 10 November 2026. Prescribing should follow current local clinical guidelines and product information.
Overview
Eicosanoids are short-lived lipid mediators made from polyunsaturated fatty acids, classically arachidonic acid. They include prostaglandins, prostacyclin, thromboxanes, leukotrienes and lipoxins, with important roles in inflammation, vascular tone, platelet function, reproduction, renal perfusion and airway biology [1].
Biosynthesis pathways
Phospholipase A2 liberates arachidonic acid from membrane phospholipids. Cyclooxygenases COX-1 and COX-2 convert it to PGH2, a precursor of PGE2, PGD2, PGF2α, prostacyclin (PGI2) and thromboxane A2 (TXA2). Lipoxygenases generate leukotrienes and other mediators; 5-lipoxygenase with FLAP participates in leukotriene synthesis. Specialized pro-resolving mediators include resolvins derived from omega-3 substrates, so not all have the same 20-carbon arachidonic-acid origin [1].
Receptor signaling
- PGE2: EP1–EP4 receptors with subtype-specific calcium or cyclic nucleotide effects.
- PGF2α: FP receptor activation can increase smooth muscle contraction.
- PGI2: IP receptor typically elevates cAMP, causing vasodilation and reduced platelet aggregation.
- TXA2: TP receptor promotes platelet aggregation and vasoconstriction.
- Leukotrienes: CysLT1 mediates bronchoconstriction and vascular permeability; LTB4 signals through BLT receptors, attracting leukocytes [1].
Important therapeutic analogues
- Ophthalmology: latanoprost, travoprost and tafluprost are FP-receptor agonists increasing uveoscleral outflow for ocular hypertension/glaucoma; bimatoprost is a prostamide analogue with related clinical effects.
- Obstetrics: dinoprostone (PGE2) supports cervical ripening, misoprostol (PGE1 analogue) is used in selected obstetric indications, and carboprost (PGF2α analogue) treats refractory uterine atony in eligible patients.
- Gastroenterology: misoprostol can reduce NSAID-associated gastric ulcer risk but is contraindicated for ulcer prevention in pregnancy.
- Pulmonary arterial hypertension: epoprostenol, treprostinil, iloprost and related prostacyclin-pathway therapies are used under specialist protocols; selexipag is a selective nonprostanoid IP-receptor agonist.
Enzyme inhibitors and leukotriene drugs
NSAIDs reduce prostaglandin synthesis through COX inhibition. Aspirin irreversibly acetylates platelet COX-1, reducing TXA2 generation for the platelet lifespan, but bleeding risk limits preventive use to selected patients. Zileuton inhibits 5-lipoxygenase; montelukast and zafirlukast block cysteinyl leukotriene receptors, not prostaglandin receptors. Rofecoxib is withdrawn in many markets and should not be listed as an ordinary currently used COX-2 inhibitor [1,2].
Safety and contraindications
NSAIDs can cause gastrointestinal bleeding, kidney injury, fluid retention and cardiovascular harm. Ophthalmic prostaglandin analogues may cause conjunctival hyperemia, iris pigmentation and eyelash growth. Misoprostol causes diarrhea and can stimulate uterine contraction; its indication and pregnancy context are decisive. Carboprost is generally avoided in asthma due to bronchospasm; prostacyclin therapies may cause flushing, headache and hypotension. Montelukast carries a neuropsychiatric boxed warning [1,2].
Clinical takeaway
Distinguish endogenous pathways from therapeutic analogues and from drugs that inhibit their synthesis. The biologic effects of prostanoids are highly receptor-dependent; do not assume all prostaglandins produce the same vascular or uterine response [1].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- US Food and Drug Administration. Montelukast sodium: boxed warning for serious neuropsychiatric events. 2026. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da038cf6-cfad-43a4-ab8e-d81d028d6087
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.